bluebird bio Inc. (NASDAQ:BLUE) went up by 3.83% from its latest closing price compared to the recent 1-year high of $99.36. The company’s stock price has collected 16.47% of gains in the last five trading sessions. Barron’s reported on 01/11/21 that Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs
Is It Worth Investing in bluebird bio Inc. (NASDAQ :BLUE) Right Now?
Plus, the 36-month beta value for BLUE is at 1.74. Opinions of the stock are interesting as 15 analysts out of 24 who provided ratings for bluebird bio Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 8 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $79.80, which is $27.88 above the current price. BLUE currently public float of 66.04M and currently shorts hold a 10.53% ratio of that float. Today, the average trading volume of BLUE was 1.07M shares.
BLUE’s Market Performance
BLUE stocks went up by 16.47% for the week, with a monthly jump of 22.81% and a quarterly performance of -10.38%, while its annual performance rate touched -39.59%. The volatility ratio for the week stands at 6.01% while the volatility levels for the past 30 days are set at 4.81% for bluebird bio Inc.. The simple moving average for the period of the last 20 days is 15.30% for BLUE stocks with a simple moving average of -5.49% for the last 200 days.
Analysts’ Opinion of BLUE
Stifel gave a rating of “Hold” to BLUE, setting the target price at $51 in the report published on November 05th of the previous year.
BLUE Trading at 13.50% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.33% of loss for the given period.
Volatility was left at 4.81%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares surge +23.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.06% lower at present.
During the last 5 trading sessions, BLUE rose by +16.47%, which changed the moving average for the period of 200-days by +9.55% in comparison to the 20-day moving average, which settled at $45.88. In addition, bluebird bio Inc. saw 20.94% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BLUE starting from FINGER ALISON CECILY, who sale 1,814 shares at the price of $45.05 back on Jan 06. After this action, FINGER ALISON CECILY now owns 25,103 shares of bluebird bio Inc., valued at $81,727 using the latest closing price.
Baird William D III, the Chief Financial Officer of bluebird bio Inc., sale 949 shares at $45.05 during a trade that took place back on Jan 06, which means that Baird William D III is holding 22,797 shares at $42,756 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -1817.79 for the present operating margin
- +54.31 for the gross margin
The net margin for bluebird bio Inc. stands at -1767.49. The total capital return value is set at -46.20, while invested capital returns managed to touch -45.20. Equity return is now at value -45.80, with -35.10 for asset returns.
Based on bluebird bio Inc. (BLUE), the company’s capital structure generated 14.86 points at debt to equity in total, while total debt to capital is 12.94. Total debt to assets is 11.06, with long-term debt to equity ratio resting at 13.29. Finally, the long-term debt to capital ratio is 11.57.
When we switch over and look at the enterprise to sales, we see a ratio of 87.92, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 4,702.53 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.15.